2,2-二乙基-6-甲氧基-3,4-二氢萘-1(2H)-酮 | 149456-21-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 2,2-二乙基-6-甲氧基-3,4-二氢萘-1(2H)-酮
• 英文名称: 2,2-diethyl-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-one
• 英文别名: 2,2-diethyl-6-methoxy-3,4-dihydro-2H-naphthalen-1-one；2,2-diethyl-6-methoxy-3,4-dihydronaphthalen-1(2H)-one；2,2-diethyl-6-methoxy-3,4-dihydronaphthalen-1-one
• CAS: 149456-21-3
• 化学式: C₁₅H₂₀O₂
• 分子量: 232.323
• InChiKey: JTJMCVUCVYQEFN-UHFFFAOYSA-N

物化性质

• 沸点：
  355.7±31.0 °C(Predicted)
• 密度：
  1.008±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-二乙基-6-甲氧基-3,4-二氢萘-1(2H)-酮 在 吡啶 、 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 氢溴酸 、 间氯过氧苯甲酸 、 二溴三苯基膦 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 6-bromo-2,2-diethyl-1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)naphthalen-1-one
  参考文献：
  名称：

  2,2-Dialkylnaphthalen-1-ones as new potassium channel activators

  摘要：

  A new series of 2,2-dialkylnaphthalen-1-one potassium channel activators has been prepared, and their in vitro relaxant activities in isolated rat portal vein and guinea pig tracheal spirals as well as their oral antihypertensive effect in spontaneously hypertensive rats have been evaluated. The group of 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethylnaphthalen-1-ones with an electron-withdrawing substituent at the 6-position contain the most active compounds and 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-c arbonitrile, 17f (UR-8225), has been selected for further pharmacological development.

  DOI：

  10.1021/jm00067a011
• 作为产物：
  描述：

  碘乙烷 、 6-甲氧基-1-萘满酮 在 sodium hydride 作用下， 以 苯 为溶剂， 生成 2,2-二乙基-6-甲氧基-3,4-二氢萘-1(2H)-酮
  参考文献：
  名称：

  2,2-Dialkylnaphthalen-1-ones as new potassium channel activators

  摘要：

  A new series of 2,2-dialkylnaphthalen-1-one potassium channel activators has been prepared, and their in vitro relaxant activities in isolated rat portal vein and guinea pig tracheal spirals as well as their oral antihypertensive effect in spontaneously hypertensive rats have been evaluated. The group of 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethylnaphthalen-1-ones with an electron-withdrawing substituent at the 6-position contain the most active compounds and 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-c arbonitrile, 17f (UR-8225), has been selected for further pharmacological development.

  DOI：

  10.1021/jm00067a011

文献信息

• Organic Compounds
  申请人：Barnes David

  公开号：US20080262050A1

  公开（公告）日：2008-10-23

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  式(I)的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，例如SH2结构域。式(I)的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐症、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗。这些疾病包括2型糖尿病的伴随症状，如高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症，以及脂质代谢紊乱和其他胰岛素抵抗相关的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• Tetralones with pharmacological activity
  申请人：J. URIACH & CIA. S.A.

  公开号：EP0489300A2

  公开（公告）日：1992-06-10

  57 The present invention relates to new tetralones having the formula I: wherein: R1 and R2 represent hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl, pentafluoroethyl, ethynyl, trimethylsilylethynyl, C1-4 alkylcarbonylamino being the amino optionally substituted by a C, -4 alkyl group; R3 is hydrogen or C1-4 alkyl, and R4 is C1-4 alkyl, or R3 and R4 together form a C2-5 polymethylene chain; either R5 represents hydroxyl, acetoxy or formyloxy and R6 and R7 are both hydrogen, or R5 together with R6 form a carbonyl group and R7 hydrogen, or R5 and R7 together form a bond and R6 is hydrogen; R8 is, among others, 1,2-dihydro-2-oxo-1-pyridyl, 2,3-dihydro-1-oxo-1H-isoindol-2-yl, 2-oxo-1-pyrrolidinyl, 2-oxo-1- pyperidinyl. The invention also relates to a procedure for their preparation and to pharmaceutical compositions containing them. These compounds are antihypertensive and bronchodilator agents.

  57 本发明涉及具有式 I 的新四萘酮： 其中 R1和R2代表氢、卤素、氰基、C1-4烷基、C1-4烷氧基、三氟甲基、五氟乙基、乙炔基、三甲基硅烷基乙炔基、C1-4烷基羰基氨基，其中氨基任选被C,-4烷基取代；R3是氢或C1-4烷基，R4是C1-4烷基，或R3和R4一起形成C2-5多亚甲基链；R5代表羟基、乙酰氧基或甲酰氧基，R6和R7均为氢，或R5与R6一起形成羰基，R7为氢，或R5与R7一起形成键，R6为氢；R8除其他外，为1,2-二氢-2-氧代-1-吡啶基、2,3-二氢-1-氧代-1H-异吲哚-2-基、2-氧代-1-吡咯烷基、2-氧代-1-哌啶基。本发明还涉及它们的制备方法和含有它们的药物组合物。这些化合物是抗高血压和支气管扩张剂。
• ORGANIC COMPOUNDS
  申请人：Novartis Pharma AG

  公开号：EP1963292A2

  公开（公告）日：2008-09-03
• US5208246A
  申请人：——

  公开号：US5208246A

  公开（公告）日：1993-05-04
• US5272170A
  申请人：——

  公开号：US5272170A

  公开（公告）日：1993-12-21